WO2000032211A1 - Enteral pharmaceutical preparation - Google Patents
Enteral pharmaceutical preparation Download PDFInfo
- Publication number
- WO2000032211A1 WO2000032211A1 PCT/IB1999/001900 IB9901900W WO0032211A1 WO 2000032211 A1 WO2000032211 A1 WO 2000032211A1 IB 9901900 W IB9901900 W IB 9901900W WO 0032211 A1 WO0032211 A1 WO 0032211A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- preparation
- oil
- fatty acids
- black cumin
- oleum lini
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 18
- 244000090896 Nigella sativa Species 0.000 claims abstract description 34
- 235000016698 Nigella sativa Nutrition 0.000 claims abstract description 34
- 239000003921 oil Substances 0.000 claims abstract description 25
- 235000019198 oils Nutrition 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 235000021388 linseed oil Nutrition 0.000 claims abstract description 18
- 239000000944 linseed oil Substances 0.000 claims abstract description 18
- 239000001711 nigella sativa Substances 0.000 claims abstract description 13
- 235000005911 diet Nutrition 0.000 claims abstract description 9
- 230000000378 dietary effect Effects 0.000 claims abstract description 9
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 8
- 201000004681 Psoriasis Diseases 0.000 claims description 13
- 239000010692 aromatic oil Substances 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 claims description 4
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 235000004626 essential fatty acids Nutrition 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 239000008158 vegetable oil Substances 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 6
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 235000021152 breakfast Nutrition 0.000 description 3
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 2
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 2
- OTYVBQZXUNBRTK-UHFFFAOYSA-N 3,3,6-trimethylhepta-1,5-dien-4-one Chemical compound CC(C)=CC(=O)C(C)(C)C=C OTYVBQZXUNBRTK-UHFFFAOYSA-N 0.000 description 2
- 239000005973 Carvone Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 2
- 229930006722 beta-pinene Natural products 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 2
- USMNOWBWPHYOEA-XKSSXDPKSA-N (+)-beta-thujone Chemical compound O=C([C@H]1C)C[C@@]2(C(C)C)[C@@H]1C2 USMNOWBWPHYOEA-XKSSXDPKSA-N 0.000 description 1
- 229930007107 (+)-beta-thujone Natural products 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 238000003302 UV-light treatment Methods 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229930007108 beta-thujone Natural products 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- the present invention relates to an enteral pharmaceutical preparation.
- an enteral pharmaceutical preparation includes black cumin oil (nigella sativa).
- the preparation may further include dietary polyunsaturated fatty acids.
- the dietary polyunsaturated fatty acids may include flax oil (oleum lini).
- an enteral pharmaceutical preparation includes a mixture of black cumin oil (nigella sativa) and flax oil (oleum lini).
- the black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1 :3.
- the black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1:1.
- the flax oil may be cold pressed unfiltered.
- the black cumin oil may be cold pressed.
- the preparation may include vegetable oils rich in alpha-linolenic (Omega 3) essential fatty acids.
- the preparation may include vegetable oils rich in alpha-linoleic (Omega 6) essential fatty acids.
- the preparation may include essential vitamins and minerals.
- the preparation may include the following (in percentage by mass): a) Fatty acids:
- Aromatic Oils 0.05 % Total Aromatic Oils 0.60 %
- the preparation may be used for treatment of psoriasis, arthritis, high cholesterol disorders or gout disorders.
- a method of treating psoriasis in affected persons includes the steps of enteral administration of an effective quantity of an enteral pharmaceutical preparation including black cumin oil (nigella sativa).
- a method of treating psoriasis in affected persons includes the steps of enteral administration of an effective quantity of an enternal pharmaceutical preparation including a mixure of black cumin oil (nigella sativa) and flax oil (oleum lini).
- the enteral pharmaceutical preparation may further include dietary polyunsaturated acids.
- the dietary polyunsaturated acids may include flax oil (oleum lini).
- the pharmaceutical preparation in accordance with the invention includes flax oil and black cumin oil.
- the constitutents of this pharmaceutical preparation are as follows (in percentage by mass):
- Beta-Pinene 0,104 %
- the dosage involved a total of two tablespoons (a total of 20 ml) per day, preferably at breakfast, but in stubborn cases of psoriasis, an initial dose of three to four tablespoons (30 to 40 ml per day) may be required.
- the preparation preferably is used as follows:
- Taste may be a problem and the oil can be mixed into juices or other carrier substances.
- black-cumin oil may lead to an increased appetite.
- compositions are (in percentage by mass):
- Vitamins B1 , B2, B6, Folic Acid, Niacine.
- the preparation preferably is used as follows: Adults: 2 tablespoons ("large spoon")
- the healing process must first commence, after which the "thick skin” will slowly peel off, displaying new pinkish skin areas.
- the pink colour is due to the fact that new skin must first develop melanin.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an enteral pharmaceutical preparation, which include black cumin oil (nigella sativa). The preparation may further includes dietary polyunsaturated fatty acids, such as flax oil (oleum lini).
Description
Enteral pharmaceutical preparation.
FIELD OF INVENTION
The present invention relates to an enteral pharmaceutical preparation.
BACKGROUND TO INVENTION
Many people all over the world suffer from the condition known as psoriasis.
The skin of human beings is constantly being renewed. Thereby, as fast as dead cells in the outermost skin layer or epidermis are shed, they are being replaced by cells from the base of the epidermis. Psoriasis takes place when this procedure of replacement becomes "unbalanced", that is when the production of new cells increases while the shedding of dead cells remains normal. This has as consequence that the live cells accumulate and produce sections of inflamed, thickened skin covered by scales. Some persons suffer from extensive affected skin areas, which is unpleasant to view and causes discomfort.
Various creams, ointments, injections and UV light treatments are known for treating psoriasis. However, there is no complete cure for psoriasis and none of the treatments appear to have any lasting effects on the vast majority of sufferers, and many of the remedies cause undesirable side effects.
Even though the condition of psoriasis has been medically identified for more than 100 years, no satisfactory treatment or cure has been found.
Worldwide, more and more people develop psoriatic symptoms, with the highest rate of increase observed in the "developed industrialised" world.
It is an object of the invention to suggest a novel enteral pharmaceutical preparation for treatment of psoriasis, as well as other dermatological disorders.
SUMMARY OF INVENTION
According to the invention, an enteral pharmaceutical preparation includes black cumin oil (nigella sativa).
The preparation may further include dietary polyunsaturated fatty acids.
The dietary polyunsaturated fatty acids may include flax oil (oleum lini).
Also according to the invention, an enteral pharmaceutical preparation includes a mixture of black cumin oil (nigella sativa) and flax oil (oleum lini).
The black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1 :3.
The black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1:1.
The flax oil may be cold pressed unfiltered.
The black cumin oil may be cold pressed.
The preparation may include vegetable oils rich in alpha-linolenic (Omega 3) essential fatty acids.
The preparation may include vegetable oils rich in alpha-linoleic (Omega 6) essential fatty acids.
The preparation may include essential vitamins and minerals. The preparation may include the following (in percentage by mass): a) Fatty acids:
Omega 3 (Linolenic) 40.1 % Omega 6 (Linoleic) 29.2 %
Oleic 18.8 %
Palmitic 6.7 %
Stearic 3.3 %
Myristic 0.1 % Palmitoleic 0.1 %
Arachidic 0.2 %
Gadoleic 0.2 %
Other fatty acids 0.7 %
Total fatty acids 99.4 % b) Aromatic Oils:
P-Cymene 0.25 %
Thymo-Hydrochinone 0.21 %
Alpha-Pinene 0.09 %
Other Aromatic Oils 0.05 % Total Aromatic Oils 0.60 %
Total Oil Content: 100.00 %
The preparation may be used for treatment of psoriasis, arthritis, high cholesterol disorders or gout disorders.
Also according to the invention, a method of treating psoriasis in affected persons, includes the steps of enteral administration of an effective quantity of an enteral pharmaceutical preparation including black cumin oil (nigella sativa).
Yet further according to the invention, a method of treating psoriasis in affected persons includes the steps of enteral administration of an effective quantity of an enternal pharmaceutical preparation including a mixure of black cumin oil (nigella sativa) and flax oil (oleum lini).
The enteral pharmaceutical preparation may further include dietary polyunsaturated acids.
The dietary polyunsaturated acids may include flax oil (oleum lini).
DESCRIPTION OF PREFERRED EXAMPLES
Example 1
In this example the pharmaceutical preparation in accordance with the invention includes flax oil and black cumin oil. The constitutents of this pharmaceutical preparation are as follows (in percentage by mass):
Summary:
Total polyunsat. 75.3%
Mono-unsaturates 16.4 %
Saturates 8.3 % Total 100.0 %
In the above the flax oil and Black-Cumin oil respectively are composed as follows:
Black-Cumin Oil: a) Fattv Acid Composition:
Myristic 0.2 %
Palmitic 12.4 %
Palmitoleic 0.2 %
Stearic 2.7 %
Oleic 23.7 %
Omega 6 (Linoleic) 57.2 %
Omega 3 (Linolenic) 0.2 %
Arachidic 0.4 %
Gadoleic 0.4 %
Other 0.6 %
Total fatty acids 98.0 % b) Aromatic Oil Composition:
Alpha Terpinene 0,018 %
P-Cymene 0,750 %
Carvone 0,008 %
Thymo-Hydrochinene 0,618 %
Alpha-Pinene 0,272 %
Beta-Pinene 0,104 %
Limonene 0,070 %
Others 0,160 %
Total Aromatic Oils 2,0 %
Flax oil:
Omega 3 (Linolenic) 60.1 %
Omega 6 (Linoleic) 15.2 %
Oleic 16.4 %
Palmitic 3.9 %
Stearic 3.6 %
Other 0.8 %
Total 100.0 %
From the above it can be seen that the total fatty acids constitute up to 98 % of the black-cumin oil, and aromatic oils total 2 % by mass respectively.
In one example of treatment, the dosage involved a total of two tablespoons (a total of 20 ml) per day, preferably at breakfast, but in stubborn cases of psoriasis, an initial dose of three to four tablespoons (30 to 40 ml per day) may be required.
The preparation preferably is used as follows:
Adults: 2 tablespoons (20 ml) per day
Children: 3 to 5 years: 1 teaspoon (5 ml) per day 6 to 10 years: 2 teaspoons (10 ml) per day
10 to 16 years: 3 teaspoons (15 ml) per day
with breakfast.
Taste may be a problem and the oil can be mixed into juices or other carrier substances.
It has been found that black-cumin oil may lead to an increased appetite.
Where the oral intake of oils is disliked, it is advised to mix the pharmceutical preparation in accordance with the invention into salads and yoghurt or other suitable carrier dishes.
In the case of patients suffering from diabetes it must be noted that black-cumin oil may lead to low blood sugar (hypoglycaemia), and such a patient's insulin requirements may have to be adjusted accordingly. For this reason diabetes patients have to remain under strict medical supervision until the effects of the pharmaceutical preparation on blood sugar levels have been reliably established.
Example 2
In this example in summary the following is included (in percentage by mass):
Total poly-unsaturated fatty acids 69.3 %
Total mono-unsaturated fatty acids 18.8 %
Saturated fatty acids 11.3 %
Total aromatic oils 0.6 %
Total 100.0 %
Of the above groupings the compositions are (in percentage by mass):
a) Fatty acids:
Omega 3 (Linolenic) 40.1 %
Omega 6 (Linoleic) 29.2 %
Oleic 18.8 %
Palmitic 6.7 %
Stearic 3.3 %
Myristic 0.1 %
Palmitoleic 0.1 %
Arachidic 0.2 %
Gadoleic 0.2 %
Other 0.7 %
Total fatty acids 99.4 %
b) Aromatic Oils:
P-Cymene 0.25 %
Thymo-Hydrochinone 0.21 %
Alpha-Pinene 0.09 %
Other 0.05 %
Total aromatic oils 0.60 %
Sum Total: 100.00 %
The other aromatic oils (sum total 0.05 %) included:
Carvone, Beta-Pinene, Limonene, Behemic Acid, Sabinene, 1 ,8-Cinchole, Artemisia-Ketone, Linalool, Beta-Thujone, Bornyl-Acetate, Carvacrole, Thymole, and others.
In traces the following are provided:
Vitamins: B1 , B2, B6, Folic Acid, Niacine.
Minerals: Iron, Calcium, Magnesium, Zinc, Selenium
Various Amino Acids and Enzymes.
The preparation preferably is used as follows: Adults: 2 tablespoons ("large spoon")
children: 3 to 5 years: 1 teaspoon
6 to 10 years: 2 teaspoons
10 to 16 years: 3 teaspoons
per day with breakfast.
First improvements are normally noticed after three to four weeks, sometimes sooner, sometimes later. 90 % of patients fall within the 3 to 4 weeks category.
The healing process must first commence, after which the "thick skin" will slowly peel off, displaying new pinkish skin areas. The pink colour is due to the fact that new skin must first develop melanin.
The process of healing and regeneration will require several months, varying from individual to individual. Optimum levels of improvement will be reached after approximately 6 months, sometimes sooner, sometimes later.
Claims
1. An enteral pharmaceutical preparation, which includes black cumin oil (nigella sativa).
2. A preparation as claimed in claim 1 , which further includes dietary polyunsaturated fatty acids.
3. A preparation as claimed in claim 2, in which the dietary polyunsaturated fatty acids include flax oil (oleum lini).
4. An enteral pharmaceutical preparation, which includes a mixture of black cumin oil (nigella sativa) and flax oil (oleum lini).
5. A preparation as claimed in claim 4, in which the black cumin oil (nigella sativa) and the flax oil (oleum lini) are provided in a proportion by mass of about 1 :3.
6. A preparation as claimed in claim 4, in which the black cumin oil (nigella sativa) and the flax oil (oleum lini) are provided in a proportion by mass of about 1 :1.
7. A preparation as claimed in any one of claims 3 to 6, in which the flax oil is cold pressed unfiltered.
8. A preparation as claimed in any one of the preceding claims, in which the black cumin oil is cold pressed.
9. A preparation as claimed in any one of the preceding claims, which includes vegetable oils rich in alpha-linolenic (Omega 3) essential fatty acids.
10. A preparation as claimed in any one of the preceding claims, which includes vegetable oils rich in alpha-linoleic (Omega 6) essential fatty acids.
11. A preparation as claimed in any one of the preceding claims, which includes essential vitamins and minerals.
12. A preparation as claimed in any one of claims 3 to 11 , which includes (in percentage by mass): a) Fattv acids:
Omega 3 (Linolenic)40.1 %
Omega 6 (Linoleic)29.2 %
Oleic 18.8 %
Palmitic 6.7 %
Stearic 3.3 %
Myristic 0.1 %
Palmitoleic 0.1 %
Arachidic 0.2 %
Gadoleic 0.2 % Other fatty acids 0.7 %
Total fatty acids 99.4 % b) Aromatic Oils
P-Cymene 0.25 %
Thymo-Hydrochinone 0.21 % Alpha-Pinene 0.09 %
Other Aromatic Oils 0.05 % Total Aromatic Oils 0.60 %
Total Oil Content: 100.00 %
13. A preparation as claimed in any one of the preceding claims, which is to be used for treatment of psoriasis.
14. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of arthritis.
15. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of high cholesterol disorders.
16. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of gout disorders.
17. A method of treating psoriasis in affected persons, which includes the steps of entemal administration of an effective quantity of an enternal pharmaceutical preparation including black cumin oil (nigella sativa).
18. A method of treating psoriasis in affected persons, which includes the steps of enteral administration of an effective quantity of an enternal pharmaceutical preparation including a mixure of black cumin oil (nigella sativa) and flax oil (oleum lini).
19. A method as claimed in claim 17 or claim 18, in which the enteral pharmaceutical preparation further includes dietary polyunsaturated fatty acids.
20. A method as claimed in claim 19, in which the dietary polyunsaturated fatty acids include flax oil (oleum lini).
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE69905939T DE69905939D1 (en) | 1998-12-03 | 1999-11-29 | ENTERAL PHARMACEUTICAL PREPARATION |
| EP99972923A EP1135148B1 (en) | 1998-12-03 | 1999-11-29 | Enteral pharmaceutical preparation |
| US09/856,955 US6531164B1 (en) | 1998-12-03 | 1999-11-29 | Enteral pharmaceutical preparation |
| AT99972923T ATE234106T1 (en) | 1998-12-03 | 1999-11-29 | ENTERAL PHARMACEUTICAL PREPARATION |
| AU11737/00A AU1173700A (en) | 1998-12-03 | 1999-11-29 | Enteral pharmaceutical preparation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA9811046 | 1998-12-03 | ||
| ZA98/11046 | 1998-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2000032211A1 true WO2000032211A1 (en) | 2000-06-08 |
Family
ID=25587434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB1999/001900 WO2000032211A1 (en) | 1998-12-03 | 1999-11-29 | Enteral pharmaceutical preparation |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6531164B1 (en) |
| EP (1) | EP1135148B1 (en) |
| AT (1) | ATE234106T1 (en) |
| AU (1) | AU1173700A (en) |
| DE (1) | DE69905939D1 (en) |
| ES (1) | ES2195666T3 (en) |
| WO (1) | WO2000032211A1 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012753A1 (en) * | 2002-07-31 | 2004-02-12 | Helfried Hans Rudolf Crede | Pharmaceutical composition containing black cumin oil, flax oil and borago oil |
| WO2005009332A2 (en) * | 2003-07-31 | 2005-02-03 | Palsamed (P.B.S.) Ltd. | Compositions-of-matter for lowering serum cholesterol and/or triglyceride level and methods of producing and using same |
| WO2010050794A1 (en) * | 2008-10-28 | 2010-05-06 | Universiti Putra Malaysia | Cardioprotective effects of nutraceuticals isolated from nigella sativa seeds |
| US7897194B2 (en) * | 2006-04-18 | 2011-03-01 | Botanic Oil Innovations, Inc. | Synergistic super potent antioxidant cold pressed botanic oil blends |
| US8221739B2 (en) | 2004-04-29 | 2012-07-17 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
| US8449925B2 (en) * | 2004-04-29 | 2013-05-28 | Botanic Oil Innovations, Inc. | Method and use of cold-pressed botanic seed oils for lowering blood pressure and LDL cholesterol |
| EP2745841A1 (en) * | 2012-12-19 | 2014-06-25 | DurrDerma Healthcare GmbH | Compositions for the treatment of dermatological conditions, disorders or diseases |
| US11576936B2 (en) | 2016-12-07 | 2023-02-14 | Salspera, Llc | Methods of synergistic treatment of cancer |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140213558A1 (en) * | 2011-08-26 | 2014-07-31 | Crede Oils (Pty) Ltd | Treatment of inflammatory disease or disorder and compositions therefor |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728168A1 (en) * | 1994-12-20 | 1996-06-21 | El Khani Abdallah | Compsns. for stimulating hair regrowth, eradicating dandruff and nail care |
| US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
-
1999
- 1999-11-29 EP EP99972923A patent/EP1135148B1/en not_active Expired - Lifetime
- 1999-11-29 AT AT99972923T patent/ATE234106T1/en not_active IP Right Cessation
- 1999-11-29 US US09/856,955 patent/US6531164B1/en not_active Expired - Fee Related
- 1999-11-29 WO PCT/IB1999/001900 patent/WO2000032211A1/en active IP Right Grant
- 1999-11-29 ES ES99972923T patent/ES2195666T3/en not_active Expired - Lifetime
- 1999-11-29 AU AU11737/00A patent/AU1173700A/en not_active Abandoned
- 1999-11-29 DE DE69905939T patent/DE69905939D1/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| N. BABA ET AL.: "EFFECTS OF FEEDING BLACK CUMIN OIL ON BODY COMPOSITION, SERUM LIPIDS AND ADIPOSE TISSUE LIPOPROTEIN LIPASE ACTIVITY IN RATS.", FASEB JOURNAL., vol. 10, 1996, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD., US, pages A187, XP002133719, ISSN: 0892-6638 * |
| PETER J. HOUGHTON ET AL.: "FIXED OIL OF NIGELLA SATIVA AND DERIVED THYMOQUINONE INHIBIT EICOSANOID GENERATION IN LEUKOCYTES AND MEMBRANE LIPID PEROXIDATION.", PLANTA MEDICA, vol. 61, 1995, THIEME, STUTTGART, DE, pages 33 - 36, XP000877445, ISSN: 0032-0943 * |
| SAMIR A.E. BASHANDY: "EFFECT OF NIGELLA SATIVA OIL ON LIVER AND KIDNEY FUNCTIONS OF ADULT AND SENILE RATS.", EGYPTIAN JOURNAL OF PHARMACEUTICAL SCIENCES., vol. 37, no. 1-6, 1996, NATIONAL INFORMATION AND DOCUMENTATION CENTRE, CAIRO., EG, pages 313 - 327, XP000892318, ISSN: 0301-5068 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012753A1 (en) * | 2002-07-31 | 2004-02-12 | Helfried Hans Rudolf Crede | Pharmaceutical composition containing black cumin oil, flax oil and borago oil |
| WO2005009332A2 (en) * | 2003-07-31 | 2005-02-03 | Palsamed (P.B.S.) Ltd. | Compositions-of-matter for lowering serum cholesterol and/or triglyceride level and methods of producing and using same |
| WO2005009332A3 (en) * | 2003-07-31 | 2006-02-16 | Palsamed Ltd | Compositions-of-matter for lowering serum cholesterol and/or triglyceride level and methods of producing and using same |
| US8647618B2 (en) | 2004-04-29 | 2014-02-11 | Cureium Therapeutics LLC | Method of cancer treatment |
| US8221739B2 (en) | 2004-04-29 | 2012-07-17 | Botanic Oil Innovations, Inc. | Method of cancer treatment |
| US8449925B2 (en) * | 2004-04-29 | 2013-05-28 | Botanic Oil Innovations, Inc. | Method and use of cold-pressed botanic seed oils for lowering blood pressure and LDL cholesterol |
| US7897194B2 (en) * | 2006-04-18 | 2011-03-01 | Botanic Oil Innovations, Inc. | Synergistic super potent antioxidant cold pressed botanic oil blends |
| WO2010050794A1 (en) * | 2008-10-28 | 2010-05-06 | Universiti Putra Malaysia | Cardioprotective effects of nutraceuticals isolated from nigella sativa seeds |
| EP2745841A1 (en) * | 2012-12-19 | 2014-06-25 | DurrDerma Healthcare GmbH | Compositions for the treatment of dermatological conditions, disorders or diseases |
| WO2014095049A1 (en) * | 2012-12-19 | 2014-06-26 | Durrderma Healthcare Gmbh | Compositions for the treatment of dermatological conditions, disorders or diseases |
| US9675655B2 (en) | 2012-12-19 | 2017-06-13 | Veit Hoermann Gesellschaft Für Unternehmenskommunikation Mbh | Compositions for the treatment of dermatological conditions, disorders or diseases |
| US10350256B2 (en) | 2012-12-19 | 2019-07-16 | Veit Hoermann Gesellschaft Für Unternehmenskommunikation Mbh | Compositions for the treatment of dermatological conditions, disorders or diseases |
| US11576936B2 (en) | 2016-12-07 | 2023-02-14 | Salspera, Llc | Methods of synergistic treatment of cancer |
| US12090179B2 (en) | 2016-12-07 | 2024-09-17 | Salspera, Llc | Methods of synergistic treatment of cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| US6531164B1 (en) | 2003-03-11 |
| AU1173700A (en) | 2000-06-19 |
| EP1135148B1 (en) | 2003-03-12 |
| EP1135148A1 (en) | 2001-09-26 |
| ES2195666T3 (en) | 2003-12-01 |
| ATE234106T1 (en) | 2003-03-15 |
| DE69905939D1 (en) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3138088C2 (en) | ||
| JP5173102B2 (en) | Plant-derived tryptophan source and use thereof | |
| EP1135148B1 (en) | Enteral pharmaceutical preparation | |
| DE3348162C2 (en) | ||
| HILLMAN et al. | Hypervitaminosis A: experimental induction in the human subject | |
| JP2011500016A (en) | Infant infant formula containing green tea and lactic acid bacteria | |
| CN1270697C (en) | Oral nano nourishing emulsion and its preparation method | |
| Lees | L-dopa treatment and Parkinson's disease | |
| CH712713B1 (en) | Coffee enriched with maca and how it is made. | |
| ZA200104293B (en) | Enteral pharmaceutical preparation. | |
| CN101623044A (en) | Method for producing traditional Chinese medicine black-bone chicken eggs | |
| JP2003024010A (en) | Function-enhancing supplementary food comprising as main ingredient green tea catechin | |
| US4273794A (en) | Composition containing honey | |
| KR101948047B1 (en) | Composition for relieving and improving acute facial pain containing boswellia extract | |
| US5516516A (en) | Method of preparing muira puama extract and its use for decreasing body fat percentage and increasing lean muscle mass | |
| JPH0662795A (en) | Antiallergic food | |
| EP0852469B1 (en) | Use of threonine for the treatment of phenylketonuria | |
| CN109939160A (en) | A kind of oral solution of calm nerves and preparation method thereof | |
| Kaewwongse et al. | Continuous supplementation of perilla seed oil is safe and facilitates the learning and memory in adult rats | |
| AU2021100330A4 (en) | A Kind Of Gamma-Aminobutyric Acid Composition Rich In Botanical Herbs And Its Preparation Method | |
| US4826684A (en) | Composition for, and method of, treatment of diabetes | |
| DE102007021403B4 (en) | Whole egg preparation | |
| DE10135493A1 (en) | New use of calcium compounds, e.g. calcium L-lactate, for treating hypercholesterolemia and associated diseases such as coronary heart disease | |
| KK et al. | Observations on the fedding of fatty acids from cerebrosides to patients with disseminated sclerosis. | |
| CN112957393A (en) | Composition containing folic acid and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 11737 Kind code of ref document: A Format of ref document f/p: F |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 200104293 Country of ref document: ZA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09856955 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999972923 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999972923 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1999972923 Country of ref document: EP |